Conference Coverage

BRAF-Plus-MEK Inhibition Slows Melanoma


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

The abstract can be viewed at www.abstract.asco.org, and will be formally presented at ASCO at 3:30 p.m. June 4.

The trial was funded by GlaxoSmithKline. Dr. Weber reports consulting for and receiving honoraria and research funding from GSK. His coauthors report similar relationships, as well as employment/leadership positions and stock ownership with GSK.

* Updated: This paragraph was added on May 18, 2012.

Pages

Recommended Reading

Dr. Brett M. Coldiron: Mohs Surgery Is Cost Effective
MDedge Dermatology
Spotlight on AAD Volunteers, Outreach: The Skinny Vodcast
MDedge Dermatology
Dark-Skinned Patients Not Getting Skin Cancer Message
MDedge Dermatology
USPSTF: Counsel Kids, Young Adults on Sun Exposure
MDedge Dermatology
CDC: Indoor Tanning, Sunburns Still Common in Young Adults
MDedge Dermatology
Photodamage Effectively Treated With Quasi-Ablative Approach
MDedge Dermatology
FDA Delays Sunscreen Rule by 6 Months
MDedge Dermatology
Environmental Working Group Releases Sunscreen Ranking
MDedge Dermatology
Melanoma in Skin of Color
MDedge Dermatology
Radiation Therapy Offering Hope and Excellent Cosmesis for Treatment of Nonmelanoma Skin Cancer of the Eyelid: A Retrospective Review
MDedge Dermatology